These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 27371612)
1. Intermediate microRNA expression profile in Graves' disease falls between that of normal thyroid tissue and papillary thyroid carcinoma. Pohl M; Grabellus F; Worm K; Arnold G; Walz M; Schmid KW; Sheu-Grabellus SY J Clin Pathol; 2017 Jan; 70(1):33-39. PubMed ID: 27371612 [TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505 [TBL] [Abstract][Full Text] [Related]
3. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
4. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574 [TBL] [Abstract][Full Text] [Related]
5. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features. Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472 [TBL] [Abstract][Full Text] [Related]
7. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953 [TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400 [TBL] [Abstract][Full Text] [Related]
9. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212 [TBL] [Abstract][Full Text] [Related]
10. Can cytomorphology differentiate between benign nodules and tumors arising in Graves' disease? Anderson SR; Mandel S; LiVolsi VA; Gupta PK; Baloch ZW Diagn Cytopathol; 2004 Jul; 31(1):64-7. PubMed ID: 15236269 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA Profiling in Papillary Thyroid Cancer. Armos R; Bojtor B; Papp M; Illyes I; Lengyel B; Kiss A; Szili B; Tobias B; Balla B; Piko H; Illes A; Putz Z; Kiss A; Toth E; Takacs I; Kosa JP; Lakatos P Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273308 [TBL] [Abstract][Full Text] [Related]
12. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295 [TBL] [Abstract][Full Text] [Related]
13. Variants in microRNA genes in familial papillary thyroid carcinoma. Tomsic J; Fultz R; Liyanarachchi S; Genutis LK; Wang Y; Li W; Volinia S; Jazdzewski K; He H; Wakely PE; Senter L; de la Chapelle A Oncotarget; 2017 Jan; 8(4):6475-6482. PubMed ID: 28031538 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Li D; Jian W; Wei C; Song H; Gu Y; Luo Y; Fang L Int J Clin Exp Pathol; 2014; 7(11):7672-80. PubMed ID: 25550803 [TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease. Sancak S; Hardt A; Singer J; Klöppel G; Eren FT; Güllüoglu BM; Sen LS; Sever Z; Akalin NS; Eszlinger M; Paschke R Thyroid; 2010 May; 20(5):505-11. PubMed ID: 20450431 [TBL] [Abstract][Full Text] [Related]
16. Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers. Acibucu F; Dökmetaş HS; Tutar Y; Elagoz S; Kilicli F Exp Clin Endocrinol Diabetes; 2014 Mar; 122(3):137-43. PubMed ID: 24643689 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA deregulation in human thyroid papillary carcinomas. Pallante P; Visone R; Ferracin M; Ferraro A; Berlingieri MT; Troncone G; Chiappetta G; Liu CG; Santoro M; Negrini M; Croce CM; Fusco A Endocr Relat Cancer; 2006 Jun; 13(2):497-508. PubMed ID: 16728577 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Geraldo MV; Nakaya HI; Kimura ET Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816 [TBL] [Abstract][Full Text] [Related]